Research Article

A longitudinal program for biomarker development in Parkinson's disease: A feasibility study†

  1. Bernard Ravina MD, MSCE1,*,
  2. Caroline Tanner MD, PhD2,
  3. Diane DiEuliis PhD3,
  4. Shirley Eberly MS1,
  5. Emily Flagg BA1,
  6. Wendy R. Galpern MD, PhD3,
  7. Stanley Fahn MD4,
  8. Christopher G. Goetz MD5,
  9. Stephen Grate DVM6,
  10. Roger Kurlan MD1,
  11. Anthony E. Lang MD7,
  12. Kenneth Marek MD8,
  13. Karl Kieburtz MD, MPH1,
  14. David Oakes PhD1,
  15. Robin Elliott MA9,
  16. Ira Shoulson MD1

Article first published online: 18 AUG 2009

DOI: 10.1002/mds.22690

Issue

Movement Disorders

Movement Disorders

Volume 24, Issue 14, pages 2081–2090, 30 October 2009

Additional Information

How to Cite

Ravina, B., Tanner, C., DiEuliis, D., Eberly, S., Flagg, E., Galpern, W. R., Fahn, S., Goetz, C. G., Grate, S., Kurlan, R., Lang, A. E., Marek, K., Kieburtz, K., Oakes, D., Elliott, R. and Shoulson, I. (2009), A longitudinal program for biomarker development in Parkinson's disease: A feasibility study. Mov. Disord., 24: 2081–2090. doi: 10.1002/mds.22690

Author Information

  1. 1

    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA

  2. 2

    The Parkinson's Institute, Sunnyvale, California, USA

  3. 3

    The National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, USA

  4. 4

    Department of Neurology, Columbia University, New York, New York, USA

  5. 5

    Department of Neurosciences, Rush University Medical Center, Chicago, Illinois, USA

  6. 6

    Telemedicine and Advanced Technology Research Center, Fort Detrick, Maryland, USA

  7. 7

    Department of Medicine, Division of Neurology, Univerisity of Toronto, Toronto, Ontario, Canada

  8. 8

    Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA

  9. 9

    The Parkinson's Disease Foundation, New York, New York, USA

*1351 Mt. Hope Ave., Suite 223, Rochester, NY 14620

  1. †

    Potential conflict of interest: None reported.

Publication History

  1. Issue published online: 28 OCT 2009
  2. Article first published online: 18 AUG 2009
  3. Manuscript Accepted: 10 JUN 2009
  4. Manuscript Received: 22 APR 2009

Funded by

  • National Institute of Neurological Disorders and Stroke. Grant Number: 5U01NS050095-05
  • Department of Defense Neurotoxin Exposure Treatment Parkinson's Research Program. Grant Number: W23RRYX7022N606
  • Michael J Fox Foundation
  • Parkinson's Disease Foundation
  • Lundbeck Pharmaceuticals
  • Cephalon Inc
  • Lundbeck Inc
  • John Blume Foundation
  • Smart Family Foundation
  • RJG Foundation
  • Kinetics Foundation
  • National Parkinson Foundation
  • Amarin Neuroscience LTD
  • CHDI Foundation Inc
  • National Institutes of Health (NHGRI, NINDS)
  • Columbia Parkinson's Disease Research Center

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (158K)

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • If you would like institutional access to this content, please recommend the title to your librarian.
  • Login via Athens http://onlinelibrary.wiley.com/athens or other institutional login options http://onlinelibrary.wiley.com/login-options .
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

View Full Article (HTML) Get PDF (158K)